Update of sarilumb to treat rheumatoid arthritis based on randomized clinical trials: a systematic review.

about

Update of sarilumb to treat rheumatoid arthritis based on randomized clinical trials: a systematic review.

Item

http://www.wikidata.org/entity/Q38660813

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Update of sarilumb to treat rh ...... l trials: a systematic review.

@en

type

Item

label

Update of sarilumb to treat rh ...... l trials: a systematic review.

@en

prefLabel

Update of sarilumb to treat rh ...... l trials: a systematic review.

@en

P1476

Update of sarilumb to treat rh ...... l trials: a systematic review.

@en

P2093

Aly M Aly

http://www.w3.org/2001/XMLSchema#string

Daniel E Furst

http://www.w3.org/2001/XMLSchema#string

P2860

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Emerging Therapies for Rheumatoid Arthritis

Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.

Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis.

Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)

The pro- and anti-inflammatory properties of the cytokine interleukin-6.

P304

741-752

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/1744666X.2017.1351297

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28689441

http://www.w3.org/2001/XMLSchema#string